FluvastatinHMGCR inhibitor CAS# 93957-54-1 |
- Atorvastatin Calcium
Catalog No.:BCC2319
CAS No.:134523-03-8
- Pitavastatin Calcium
Catalog No.:BCC3842
CAS No.:147526-32-7
- Lovastatin
Catalog No.:BCN1060
CAS No.:75330-75-5
- Pravastatin sodium
Catalog No.:BCC2321
CAS No.:81131-70-6
- Fluvastatin Sodium
Catalog No.:BCC2317
CAS No.:93957-55-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 93957-54-1 | SDF | Download SDF |
PubChem ID | 6347538 | Appearance | Powder |
Formula | C24H26FNO4 | M.Wt | 411.47 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Water 25 mg/ml DMSO 100 mg/ml Ethanol 25 mg/ml | ||
Chemical Name | (E,3S,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid | ||
SMILES | CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F | ||
Standard InChIKey | FJLGEFLZQAZZCD-VVZAMHAXSA-N | ||
Standard InChI | InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Fluvastatin (Leschol) inhibits HMG-CoA reductase activity with IC50 of 8 nM.
IC50 value: 8 nM
Target: HMG-CoA reductase
Fluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Human hepatocellular carcinoma cell (HCC) studies indicate that Fluvastatin induces G2/M phase arrest. In the presence of Fluvastatin, HCC cells show a decrease of Bcl-2 and procaspase-9 expression, and an increase in Bax, cleaved caspase-3, and cytochrome c. Fluvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. References: |
Fluvastatin Dilution Calculator
Fluvastatin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4303 mL | 12.1516 mL | 24.3031 mL | 48.6062 mL | 60.7578 mL |
5 mM | 0.4861 mL | 2.4303 mL | 4.8606 mL | 9.7212 mL | 12.1516 mL |
10 mM | 0.243 mL | 1.2152 mL | 2.4303 mL | 4.8606 mL | 6.0758 mL |
50 mM | 0.0486 mL | 0.243 mL | 0.4861 mL | 0.9721 mL | 1.2152 mL |
100 mM | 0.0243 mL | 0.1215 mL | 0.243 mL | 0.4861 mL | 0.6076 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Fluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Human hepatocellular carcinoma cell (HCC) studies indicate that Fluvastatin induces G2/M phase arrest. In the presence of Fluvastatin, HCC cells show a decrease of Bcl-2 and procaspase-9 expression, and an increase in Bax, cleaved caspase-3, and cytochrome c. Fluvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.
- Toonaciliatin M
Catalog No.:BCN7881
CAS No.:93930-04-2
- Hirsutanonol 5-O-glucoside
Catalog No.:BCN4485
CAS No.:93915-36-7
- FIPI
Catalog No.:BCC7721
CAS No.:939055-18-2
- 9-Oxo-2,7-bisaboladien-15-oic acid
Catalog No.:BCN4484
CAS No.:93888-59-6
- Isochamaejasmine
Catalog No.:BCN3128
CAS No.:93859-63-3
- KU-0063794
Catalog No.:BCC2484
CAS No.:938440-64-3
- ATPγS tetralithium salt
Catalog No.:BCC7855
CAS No.:93839-89-5
- 22-beta-Acetoxyglycyrrhizin
Catalog No.:BCN7904
CAS No.:938042-17-2
- 3-Prenyl-2,4,6-trihydroxybenzophenone
Catalog No.:BCN1303
CAS No.:93796-20-4
- Roxatidine Acetate HCl
Catalog No.:BCC4534
CAS No.:93793-83-0
- gamma-Secretase Modulators
Catalog No.:BCC1586
CAS No.:937812-80-1
- Neurodazine
Catalog No.:BCC7738
CAS No.:937807-66-4
- Fluvastatin Sodium
Catalog No.:BCC2317
CAS No.:93957-55-2
- [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human)
Catalog No.:BCC5719
CAS No.:93965-89-0
- PF-00562271
Catalog No.:BCC3684
CAS No.:939791-38-5
- ACTB-1003
Catalog No.:BCC5587
CAS No.:939805-30-8
- BI 6015
Catalog No.:BCC6249
CAS No.:93987-29-2
- p53 and MDM2 proteins-interaction-inhibitor chiral
Catalog No.:BCC1830
CAS No.:939981-37-0
- RG7112
Catalog No.:BCC1894
CAS No.:939981-39-2
- p53 and MDM2 proteins-interaction-inhibitor racemic
Catalog No.:BCC1831
CAS No.:939983-14-9
- Synephrine
Catalog No.:BCN6308
CAS No.:94-07-5
- Benzocaine
Catalog No.:BCC4636
CAS No.:94-09-7
- Propylparaben
Catalog No.:BCN8416
CAS No.:94-13-3
- Sodium 4-amiropparaty Hyalrate
Catalog No.:BCC3855
CAS No.:94-16-6
Release properties of atelocollagen-gelatin complexes as carriers for local administration of fluvastatin.[Pubmed:28302944]
Dent Mater J. 2017 Jul 26;36(4):408-414.
The aim of this study was to investigate properties of atelocollagen/gelatin complexes (AC/Gel) and their characteristics of sustained statin release, to assess the utility of AC/Gel. AC/Gel were prepared by changing the mixing ratio of AC (0 to 40% of AC). Analysis of spectra of Fluvastatin (Flu), gelatin (Gel), and Flu with Gel complex using a Fourier transform-infrared spectrometer indicates that Flu was bound to Gel through a bond involving the carboxyl and amino groups. Evaluation of characteristics of sustained release of Flu from the AC/Gel using an ultraviolet-visible spectrophotometer showed that the release rate of Flu decreased with increasing the AC content. The histological evaluation using of Sprague-Dawley rats suggest that, unlike the pure Gel sponge, the AC/Gel was not absorbed in an early stage. Therefore, the present study showed that sustained Flu release can be controlled by using an AC/Gel, suggesting the utility of this composite material.
Single intra-articular injection of fluvastatin-PLGA microspheres reduces cartilage degradation in rabbits with experimental osteoarthritis.[Pubmed:28303595]
J Orthop Res. 2017 Nov;35(11):2465-2475.
Statins are cholesterol-lowering drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of the mevalonate pathway. The anti-inflammatory effect of statins has been reported in recent years. The present study investigated therapeutic effects of the local administration of statin in osteoarthritis (OA). We assessed clinically used statins and selected Fluvastatin for further experimentation, as it showed potent anabolic and anti-catabolic effects on human OA chondrocytes. To achieve controlled intra-articular administration of statin, we developed an intra-articular injectable statin using poly(lactic-co-glycolic acid) (PLGA) as a drug delivery system (DDS). The release profile of the statin was evaluated in vitro. Finally, therapeutic effects of Fluvastatin-loaded PLGA microspheres (FLU-PLGA) were tested in a rabbit OA model. Rabbit knees were divided into four subgroups: group 1-A, PLGA-treated group; group 1-B, PLGA contralateral saline control group; group 2-A, FLU-PLGA-treated group; and group 2-B, FLU-PLGA contralateral saline control group. Histological analysis 5 weeks after intra-articular injection revealed that OARSI scores were lower in group 2-A. No significant differences in OARSI scores were observed between groups 1-A, 1-B, and 2-B. This study indicates that a single intra-articular injection of Fluvastatin-loaded PLGA microspheres could be a novel therapeutic approach for treating patients with OA. (c) 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:2465-2475, 2017.
Protective Effects of Fluvastatin on Reproductive Function in Obese Male Rats Induced by High-Fat Diet through Enhanced Signaling of mTOR.[Pubmed:28214901]
Cell Physiol Biochem. 2017;41(2):598-608.
BACKGROUND: Statins can reduce reproductive damage induced by obesity or high-fat diet (HFD), but the specific regulatory mechanisms are largely unknown. Since mTOR/p70s6k sinaling promotes spermatogonia proliferation and spermatogenesis, we hypothesized that this pathway will be involved in the protective effects of statin in HFD-induced reproductive dysfunction. METHODS: Male Sprague Dawley rats (3 weeks old) were randomly divided into a control group (standard diet), HFD group, and a Fluvastatin group (HFD + Fluvastatin at 6mg/kg, once daily by oral gavage). After 8 weeks, body weight was obtain and rats were sacrificed. Weights of the testes, gross morphology, sperm parameters, circulating levels of sex hormones, lipid levels, and tissue mTOR, p-P70s6k were measured. Another set of male rats were treated with rapamycin or vehicle. Flow cytometry was used to detect the spermatogonia marker c-kit and cell cycle. p-P70s6k expression was analyzed by Western blot. RESULTS: HFD not only results in rat obesity but also leads to spermatogenetic damage and Fluvastatin was able to partially block the effects of HFD. Fluvastatin also partially reversed the suppression of mTOR and p-p70s6k expresson. CONCLUSION: Our data suggest that Fluvastatin has protective effects on reproductive function in obese male rats most probably through enhanced signaling of mTOR.
Identification and characterization of fluvastatin metabolites in rats by UHPLC/Q-TOF/MS/MS and in silico toxicological screening of the metabolites.[Pubmed:28295913]
J Mass Spectrom. 2017 May;52(5):296-314.
The present study reports the in vivo and in vitro identification and characterization of metabolites of Fluvastatin, the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor, using liquid chromatography-mass spectrometry (LC-MS). In vitro studies were conducted by incubating the drug with human liver microsomes and rat liver microsomes. In vivo studies were carried out by administration of the drug in the form of suspension to the Sprague-Dawley rats followed by collection of urine, faeces and blood at different time points up to 24 h. Further, samples were prepared by optimized sample preparation method, which includes freeze liquid extraction, protein precipitation and solid phase extraction. The extracted and concentrated samples were analysed using ultrahigh-performance liquid chromatography-quadruple time-of-flight tandem mass spectrometry. A total of 15 metabolites were observed in urine, which includes hydroxyl, sulphated, desisopropyl, dehydrogenated, dehydroxylated and glucuronide metabolites. A few of the metabolites were also present in faeces and plasma samples. In in vitro studies, a few metabolites were observed that were also present in in vivo samples. All the metabolites were characterized using ultrahigh-performance liquid chromatography-quadruple time-of-flight tandem mass spectrometry in combination with accurate mass measurement. Finally, in silico toxicity studies indicated that some of the metabolites show or possess carcinogenicity and skin sensitization. Several metabolites that were identified in rats are proposed to have toxicological significance on the basis of in silico evaluation. However, these metabolites are of no human relevance. Copyright (c) 2017 John Wiley & Sons, Ltd.